Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

Wedbush analyst Martin Fan has reiterated an 'Outperform' rating on Aclaris Therapeutics (NASDAQ: ACRS) and has maintained a price target of $8 for the company's stock.